Bimekizumab versus Adalimumab in Plaque Psoriasis

R. G. Langley

doi:10.1056/NEJMoa2102388

Bimekizumab versus Adalimumab in Plaque Psoriasis

R. G. Langley

Inernational Relations Division

Research output: Contribution to journal › Article › peer-review

153 Citations (Scopus)

Original language	English
Pages (from-to)	130-141
Number of pages	12
Journal	New England Journal of Medicine
Volume	385
Issue number	2
DOIs	https://doi.org/10.1056/NEJMoa2102388
Publication status	Published - Jul 8 2021

ASJC Scopus Subject Areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJMoa2102388

Cite this

@article{fd5de7645a814d23a8e035670619f555,

title = "Bimekizumab versus Adalimumab in Plaque Psoriasis",

author = "Langley, {R. G.}",

year = "2021",

month = jul,

day = "8",

doi = "10.1056/NEJMoa2102388",

language = "English",

volume = "385",

pages = "130--141",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "2",

}

TY - JOUR

T1 - Bimekizumab versus Adalimumab in Plaque Psoriasis

AU - Langley, R. G.

PY - 2021/7/8

Y1 - 2021/7/8

UR - http://www.scopus.com/inward/record.url?scp=85108289485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108289485&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa2102388

DO - 10.1056/NEJMoa2102388

M3 - Article

C2 - 33891379

AN - SCOPUS:85108289485

SN - 0028-4793

VL - 385

SP - 130

EP - 141

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 2

ER -

Bimekizumab versus Adalimumab in Plaque Psoriasis

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this